Regulatory Affairs 30 March 2026

GSK plc wins China approval for Exdensur as hepatitis B drug bepirovirsen enters review

GSK plc wins China approval for Exdensur as hepatitis B drug bepirovirsen enters review

London, March 30, 2026, 14:08 BST. GSK notched up two regulatory milestones in China on Monday: the country gave the green light to Exdensur, its asthma therapy, and kicked off a formal review for bepirovirsen, a hepatitis B hopeful. According to a company filing, Exdensur is now approved in China for severe eosinophilic asthma in patients 12 and up. The bepirovirsen filing covers chronic hepatitis B in adults, GSK said.
March 30, 2026
Lloyds Faces Fresh Car Finance Pressure as FCA Opens Taskforce Ahead of Payout Ruling

Lloyds Faces Fresh Car Finance Pressure as FCA Opens Taskforce Ahead of Payout Ruling

Lloyds Banking Group found itself back in the spotlight Monday, with UK regulators rolling out a taskforce to target motor finance claims companies—timed just ahead of the Financial Conduct Authority’s expected release of its final compensation rules. On top of that, the bank has a 66 million pound lawsuit hanging over it from upwards of 30,000 borrowers, who say they were mis-sold car loans. Timing is crucial for Lloyds. The bank has already put aside 1.95 billion pounds for the scandal, while the FCA earlier outlined a potential 11 billion-pound hit for the industry—ranking this among the UK’s most expensive consumer finance blowups. Whatever the watchdog decides after markets shut on Monday will set the pace for payouts, determine the
March 30, 2026